Development of direct compression Acetazolamide tablet with improved bioavailability in healthy human volunteers enabled by cocrystallization with p -Aminobenzoic acid

Nimmy Kumari,Parag Roy,Sukanta Roy,Chenguang Wang,Sourav Das,Noopur Pandey,Susanta Kumar Mondal,Anirbandeep Bose,Changquan Calvin Sun,Animesh Ghosh
DOI: https://doi.org/10.1016/j.ijpharm.2024.123793
IF: 6.51
2024-01-10
International Journal of Pharmaceutics
Abstract:Pharmaceutical cocrystallization has been widely used to improve physicochemical properties of APIs. However, developing cocrystal formulation with proven clinical success remains scarce. Successful translation of a cocrystal to suitable dosage forms requires simultaneously improvement of several deficient physicochemical properties over the parent API, without deteriorating other properties critical for successful product development. In the present work, we report the successful development of a direct compression tablet product of acetazolamide (ACZ), using a 1:1 cocrystal of acetazolamide with p -aminobenzoic acid (ACZ-PABA). The ACZ-PABA tablet exhibits superior biopharmaceutical performance against the commercial tablet, DIAMOX® (250 mg), in healthy human volunteers, leading to more than 50% reduction in the required dose.
pharmacology & pharmacy
What problem does this paper attempt to address?